Evidence map›Paper›PMID 38368440›Full record

ArticleLeukemia2024

Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens.

Marie Sébert, Lucie Freiman, Cendrine Chaffaut, Agnès Guerci, Pierre Peterlin, Sylvain Thépot, Odile Beyne-Rauzy, Sophie Park, Thomas Cluzeau, Fatiha Chermat and 7 more

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. HemaSphere · 2026
    Article
  2. Germline DDX41 mutations in myeloid neoplasms: a comprehensive review.The Korean journal of internal medicine · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Myeloid neoplasms risks for germline DDX41 pathogenic variants carriers.European journal of human genetics : EJHG · 2025
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 2 countries.

Marie SébertUniversité de Paris, Unité 944/7212-GenCellDi, INSERM and Centre National de la Recherche Scientifique (CNRS), Paris, France. marie.sebert@aphp.fr.ORCID 0000-0003-4376-4097
Lucie FreimanHematology Department, Saint Louis Hospital, AP-HP, Paris, France.ORCID 0000-0001-7205-9026
Cendrine ChaffautBiostatistics Department, Saint Louis Hospital, AP-HP, Paris, France.
Agnès GuerciGroupe Francophone des Myelodysplasies, Paris, France.
Pierre PeterlinGroupe Francophone des Myelodysplasies, Paris, France.
Sylvain ThépotGroupe Francophone des Myelodysplasies, Paris, France.
Odile Beyne-RauzyGroupe Francophone des Myelodysplasies, Paris, France.
Sophie ParkGroupe Francophone des Myelodysplasies, Paris, France.
Thomas CluzeauGroupe Francophone des Myelodysplasies, Paris, France.ORCID 0000-0002-6745-1127
Fatiha ChermatGroupe Francophone des Myelodysplasies, Paris, France.
Pierre FenauxUniversité de Paris, Unité 944/7212-GenCellDi, INSERM and Centre National de la Recherche Scientifique (CNRS), Paris, France.
Claude PreudhommeHematology Laboratory, Unité 1277-Cancer Heterogeneity Plasticity and Resistance to Therapies (CANTHER), Centre Hospitalier Universitaire (CHU) de Lille, University of Lille, Institut National de la Santé et de la Recherche Médicale (INSERM), Lille, France.
Emmanuelle ClappierUniversité de Paris, Unité 944/7212-GenCellDi, INSERM and Centre National de la Recherche Scientifique (CNRS), Paris, France.
Sylvie ChevretBiostatistics Department, Saint Louis Hospital, AP-HP, Paris, France.
Lionel AdèsUniversité de Paris, Unité 944/7212-GenCellDi, INSERM and Centre National de la Recherche Scientifique (CNRS), Paris, France.ORCID 0000-0002-9020-8766
Nicolas DuployezUniversité de Paris, Unité 944/7212-GenCellDi, INSERM and Centre National de la Recherche Scientifique (CNRS), Paris, France.ORCID 0000-0002-3927-1022
Matthieu DuchmannUniversité de Paris, Unité 944/7212-GenCellDi, INSERM and Centre National de la Recherche Scientifique (CNRS), Paris, France. matthieu.duchmann@aphp.fr.ORCID 0000-0002-7299-4572
Centre National de la Recherche Scientifique · FRGroupe Francophone des Myélodysplasies · FRAssistance Publique – Hôpitaux de Paris · FRCentre Hospitalier Régional et Universitaire de Nancy · FRCentre Hospitalier Universitaire de Grenoble · FRInserm · FRInstitut universitaire du cancer de Toulouse Oncopole · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AzacitidineLeukemia, Myeloid, AcuteDEAD-box RNA HelicasesGerm CellsHumansMutationAzacitidineDDX41 protein, humanDEAD-box RNA Helicases

Identifiers

PMID38368440
OpenAlexW4391897221

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.